Phathom Pharmaceuticals, Inc. Cash Flow Statement
PHAT / Health Care|8 years of annual SEC 10-K data (FY2018-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 8 fiscal years. All figures from audited SEC 10-K filings.
Phathom Pharmaceuticals, Inc. used $167M in operating cash flow and negative free cash flow of $167M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -6.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$221.2M | -$334.3M | -$201.6M | -$197.7M | -$143.9M | -$129.1M | -$255.1M | -$1.3M |
| Depreciation & Amortization | $633.0K | $795.0K | $575.0K | $620.0K | $521.0K | $323.0K | $8.0K | $0 |
| Operating Cash Flow | -$166.8M | -$266.8M | -$137.6M | -$146.5M | -$148.5M | -$69.7M | -$36.5M | -$1.0M |
| Capital Expenditures | $229.0K | $135.0K | $1.6M | $1.0M | $328.0K | $1.0M | $132.0K | - |
| Free Cash Flow | -$167.0M | -$266.9M | -$139.2M | -$147.6M | -$148.8M | -$70.7M | -$36.6M | - |
| FCF Margin | -95.4% | -483.1% | -20412.6% | - | - | - | - | - |